Adoptive T-cell immunotherapy of chronic lymphocytic leukaemia

Best Practice and Research: Clinical Haematology

Volumn 21, Issue 3, 2008, Pages 375-389

  Foster, Aaron E ^a   Brenner, Malcolm K ^a   Dotti, Gianpietro ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

adoptive T cell transfer; cancer stem cells; CD19; CD20; chimeric antigen receptor; chronic lymphocytic leukaemia; immunoglobulins; immunotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN;

ACTIVE IMMUNIZATION; ACUTE GRANULOCYTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CYTOTOXIC T LYMPHOCYTE; GENE TRANSFER; GENETIC MANIPULATION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; LEUKEMIA RELAPSE; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; TISSUE DISTRIBUTION; TUMOR RECURRENCE;

GENE TRANSFER TECHNIQUES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LEUKEMIA, B-CELL; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; STEM CELLS; T-LYMPHOCYTES;

EID: 51349123970     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2008.08.002     Document Type: Review

References (90)

1. Rozman C., and Montserrat E. Chronic lymphocytic leukemia. The New England Journal of Medicine 333 (1995) 1052-1057
2. Fialkow P.J., Najfeld V., Reddy A.L., et al. Chronic lymphocytic leukaemia: clonal origin in a committed B-lymphocyte progenitor. Lancet 2 (1978) 444-446
3. Lee J.S., Dixon D.O., Kantarjian H.M., et al. Prognosis of chronic lymphocytic leukemia: a multivariate regression analysis of 325 untreated patients. Blood 69 (1987) 929-936
4. Montserrat E., Gomis F., Vallespi T., et al. Presenting features and prognosis of chronic lymphocytic leukemia in younger adults. Blood 78 (1991) 1545-1551
5. Rai K.R., Peterson B.L., Appelbaum F.R., et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. New England Journal of Medicine 343 (2000) 1750-1757
6. O'Brien S.M., Kantarjian H., Thomas D.A., et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. Journal of Clinical Oncology 19 (2001) 2165-2170
7. Osterborg A., Dyer M.J., Bunjes D., et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. Journal of Clinical Oncology 15 (1997) 1567-1574
8. Pavletic Z.S., Arrowsmith E.R., Bierman P.J., et al. Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia. Bone Marrow Transplantation 25 (2000) 717-722
9. Schetelig J., Thiede C., Bornhauser M., et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. Journal of Clinical Oncology 21 (2003) 2747-2753
10. Rondon G., Giralt S., Huh Y., et al. Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplantation 18 (1996) 669-672
11. Giannopoulos K., and Schmitt M. Targets and strategies for T-cell based vaccines in patients with B-cell chronic lymphocytic leukemia. Leukemia & Lymphoma 47 (2006) 2028-2036
12. Biagi E., Dotti G., Yvon E., et al. Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes. Blood 105 (2005) 2436-2442
13. Granziero L., Ghia P., Circosta P., et al. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 97 (2001) 2777-2783
14. Johnson L.A., Heemskerk B., Powell Jr. D.J., et al. Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. Journal of Immunology 177 (2006) 6548-6559
15. Gorgun G., Holderried T.A., Zahrieh D., et al. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. The Journal of Clinical Investigation 115 (2005) 1797-1805
16. Kater A.P., van Oers M.H., and Kipps T.J. Cellular immune therapy for chronic lymphocytic leukemia. Blood 110 (2007) 2811-2818
17. Wierda W.G., Cantwell M.J., Woods S.J., et al. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 96 (2000) 2917-2924
18. Biagi E., Rousseau R., Yvon E., et al. Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia. Clinical Cancer Research 11 (2005) 6916-6923
19. Morgan R.A., Dudley M.E., Wunderlich J.R., et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314 (2006) 126-129
20. Schumacher T.N. T-cell-receptor gene therapy. Nature Reviews. Immunology 2 (2002) 512-519
21. Stauss H.J., Cesco-Gaspere M., Thomas S., et al. Monoclonal T-cell receptors: new reagents for cancer therapy. Molecular Therapy : the Journal of the American Society of Gene Therapy 15 (2007) 1744-1750
22. Kuball J., Dossett M.L., Wolfl M., et al. Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood 109 (2007) 2331-2338
23. Maher J., Brentjens R.J., Gunset G., et al. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nature Biotechnology 20 (2002) 70-75
24. Khong H.T., and Restifo N.P. Natural selection of tumor variants in the generation of 'tumor escape' phenotypes. Nature Immunology 3 (2002) 999-1005
25. Gottschalk S., Ng C.Y., Perez M., et al. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood 97 (2001) 835-843
26. Xue S.A., Gao L., Hart D., et al. Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. Blood 106 (2005) 3062-3067
27. Hedrick S.M. Chimeric T cell receptor-immunoglobulin molecules: function and applications. International Reviews of Immunology 10 (1993) 279-290
28. Eshhar Z., Waks T., Gross G., et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proceedings of the National Academy of Sciences of the United States of America 90 (1993) 720-724
29. Rossig C., Bollard C.M., Nuchtern J.G., et al. Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes. International Journal of Cancer 94 (2001) 228-236
30. Heslop H.E., Ng C.Y., Li C., et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nature Medicine 2 (1996) 551-555
31. Jensen M.C., Cooper L.J., Wu A.M., et al. Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy. Cytotherapy 5 (2003) 131-138
32. Cooper L.J., Topp M.S., Serrano L.M., et al. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood 101 (2003) 1637-1644
33. Rossig C., and Brenner M.K. Chimeric T-cell receptors for the targeting of cancer cells. Acta Haematologica 110 (2003) 154-159
34. Brentjens R.J., Latouche J.B., Santos E., et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nature Medicine 9 (2003) 279-286
35. Vera J., Savoldo B., Vigouroux S., et al. T-lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B-lymphocyte derived malignant cells. Blood 108 (2006) 3890-3897
36. Zegers B.J., Maertzdorf W.J., Van Loghem E., et al. Kappa-chain deficiency. An immunoglobulin disorder. New England Journal of Medicine 294 (1976) 1026-1030
37. Mitsuyasu R.T., Anton P.A., Deeks S.G., et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. Blood 96 (2000) 785-793
38. Kershaw M.H., Westwood J.A., Parker L.L., et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clinical Cancer Research 12 (2006) 6106-6115
39. Park J.R., Digiusto D.L., Slovak M., et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Molecular Therapy : the Journal of the American Society of Gene Therapy 15 (2007) 825-833
40. Jensen M.C., Popplewell L., DiGiusto, et al. A first-in-human clinical trial of adoptive therapy using CD19-specific chimeric antigen receptor re-directed T-cells for recurrent/refractory follicular lymphoma. [abstract]. Blood 110 (2008) 92a
41. Finney H.M., Lawson A.D., Bebbington C.R., et al. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. Journal of Immunology 161 (1998) 2791-2797
42. Pule M.A., Straathof K.C., Dotti G., et al. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Molecular Therapy : the Journal of the American Society of Gene Therapy 12 (2005) 933-941
43. Kowolik C.M., Topp M.S., Gonzalez S., et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Research 66 (2006) 10995-11004
44. Loskog A., Giandomenico V., Rossig C., et al. Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. Leukemia 20 (2006) 1819-1828
45. Dannull J., Su Z., Rizzieri D., et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. The Journal of Clinical Investigation 115 (2005) 3623-3633
46. Bollard C.M., Rossig C., Calonge M.J., et al. Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood 99 (2002) 3179-3187
47. Park C.H., Bergsagel D.E., and McCulloch E.A. Mouse myeloma tumor stem cells: a primary cell culture assay. Journal of the National Cancer Institute 46 (1971) 411-422
48. Bonnet D., and Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Medicine 3 (1997) 730-737
49. Reya T., Morrison S.J., Clarke M.F., et al. Stem cells, cancer, and cancer stem cells. Nature 414 (2001) 105-111
50. Dameshek W. Chronic lymphocytic leukemia - an accumulative disease of immunologically incompetent lymphocytes. Blood 29 Suppl (1967) 84
51. Caligaris-Cappio F., and Hamblin T.J. B-cell chronic lymphocytic leukemia: a bird of a different feather. Journal of Clinical Oncology 17 (1999) 399-408
52. Pezzella F., Tse A.G., Cordell J.L., et al. Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation. The American Journal of Pathology 137 (1990) 225-232
53. Schena M., Larsson L.G., Gottardi D., et al. Growth- and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukemia cells. Blood 79 (1992) 2981-2989
54. Kitada S., Zapata J.M., Andreeff M., et al. Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. British Journal of Haematology 106 (1999) 995-1004
55. Lankester A.C., van Schijndel G.M., van der Schoot C.E., et al. Antigen receptor nonresponsiveness in chronic lymphocytic leukemia B cells. Blood 86 (1995) 1090-1097
56. Chiorazzi N., and Ferrarini M. Evolving view of the in-vivo kinetics of chronic lymphocytic leukemia B cells. Hematology / the Education Program of the American Society of Hematology 512 (2006) 273-278
57. Andreeff M., Darzynkiewicz Z., Sharpless T.K., et al. Discrimination of human leukemia subtypes by flow cytometric analysis of cellular DNA and RNA. Blood 55 (1980) 282-293
58. Meinhardt G., Wendtner C.M., and Hallek M. Molecular pathogenesis of chronic lymphocytic leukemia: factors and signaling pathways regulating cell growth and survival. Journal of Molecular Medicine 77 (1999) 282-293
59. Hellerstein M.K. Measurement of T-cell kinetics: recent methodologic advances. Immunology Today 20 (1999) 438-441
60. Messmer B.T., Messmer D., Allen S.L., et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. The Journal of Clinical Investigation 115 (2005) 755-764
61. Damle R.N., Temburni S., Calissano C., et al. CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells. Blood 110 (2007) 3352-3359
62. Vrhovac R., Delmer A., Tang R., et al. Prognostic significance of the cell cycle inhibitor p27Kip1 in chronic B-cell lymphocytic leukemia. Blood 91 (1998) 4694-4700
63. Ringshausen I., Peschel C., and Decker T. Mammalian target of rapamycin (mTOR) inhibition in chronic lymphocytic B-cell leukemia: a new therapeutic option. Leukemia & Lymphoma 46 (2005) 11-19
64. Goodell M.A., Brose K., Paradis G., et al. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. The Journal of Experimental Medicine 183 (1996) 1797-1806
65. Goodell M.A., Rosenzweig M., Kim H., et al. Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nature Medicine 3 (1997) 1337-1345
66. Challen G.A., and Little M.H. A side order of stem cells: the SP phenotype. Stem Cells 24 (2006) 3-12
67. Wulf G.G., Wang R.Y., Kuehnle I., et al. A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 98 (2001) 1166-1173
68. Hirschmann-Jax C., Foster A.E., Wulf G.G., et al. A distinct 'side population' of cells with high drug efflux capacity in human tumor cells. Proceedings of the National Academy of Sciences of the United States of America 101 (2004) 14228-14233
69. Kondo T., Setoguchi T., and Taga T. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proceedings of the National Academy of Sciences of the United States of America 101 (2004) 781-786
70. Chiba T., Kita K., Zheng Y.W., et al. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 44 (2006) 240-251
71. Patrawala L., Calhoun T., Schneider-Broussard R., et al. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Research 65 (2005) 6207-6219
72. Zhou J., Wulfkuhle J., Zhang H., et al. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proceedings of the National Academy of Sciences of the United States of America 104 (2007) 16158-16163
73. Matsui W., Wang Q., Barber J.P., et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Research 68 (2008) 190-197
74. Kayo H., Yamazaki H., Nishida H., et al. Stem cell properties and the side population cells as a target for interferon-alpha in adult T-cell leukemia/lymphoma. Biochemical and Biophysical Research Communications 364 (2007) 808-814
75. Rooney C.M., Smith C.A., Ng C.Y., et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345 (1995) 9-13
76. Dudley M.E., Wunderlich J.R., Robbins P.F., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298 (2002) 850-854
77. Straathof K.C., Bollard C.M., Popat U., et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 105 (2005) 1898-1904
78. Bollard C.M., Gottschalk S., Leen A.M., et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 110 (2007) 2838-2845
79. Giannopoulos K., Li L., Bojarska-Junak A., et al. Expression of RHAMM/CD168 and other tumor-associated antigens in patients with B-cell chronic lymphocytic leukemia. International Journal of Oncology 29 (2006) 95-103
80. Brickner A.G., Evans A.M., Mito J.K., et al. The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL. Blood 107 (2006) 3779-3786
81. Bonnet D., Warren E.H., Greenberg P.D., et al. CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. Proceedings of the National Academy of Sciences of the United States of America 96 (1999) 8639-8644
82. Rosinski K.V., Fujii N., Mito J.K., et al. DDX3Y encodes a class I MHC-restricted H-Y antigen that is expressed in leukemic stem cells. Blood 111 (2008) 4817-4826
83. Steele J.C., Torr E.E., Noakes K.L., et al. The polycomb group proteins, BMI-1 and EZH2, are tumour-associated antigens. British Journal of Cancer 95 (2006) 1202-1211
84. Raaphorst F.M., Meijer C.J., Fieret E., et al. Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene. Neoplasia 5 (2003) 481-488
85. Lessard J., and Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 423 (2003) 255-260
86. Bracken A.P., Pasini D., Capra M., et al. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. The EMBO Journal 22 (2003) 5323-5335
87. Ranheim E.A., and Kipps T.J. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. The Journal of Experimental Medicine 177 (1993) 925-935
88. Takahashi S., Rousseau R.F., Yotnda P., et al. Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes. Human Gene Therapy 12 (2001) 659-670
89. Wierda W.G., Kipps T.J., and Keating M.J. Novel immune-based treatment strategies for chronic lymphocytic leukemia. Journal of Clinical Oncology 23 (2005) 6325-6332
90. Laytragoon-Lewin N., Rossmann E.D., Castro J., et al. Significance of phosphotyrosine proteins, Bcl-2 and p53 for apoptosis in resting B-chronic lymphocytic leukemia (CLL) cells. International Journal of Cancer 97 (2002) 344-348